CSIMarket
 
Regenicin Inc   (RGIN)
Other Ticker:  
 
 
Price: $0.0001 $0.00 0.000%
Day's High: $0.0001 Week Perf: -95.24 %
Day's Low: $ 0.00 30 Day Perf: -93.33 %
Volume (M): 10 52 Wk High: $ 0.01
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 153
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0

Regenicin Inc
Regenicin Inc is a biotechnology company that specializes in the development and commercialization of innovative regenerative medicine products. The company focuses on advanced tissue engineering and regenerative therapies for the treatment of various medical conditions. Regenicin is committed to identifying novel technologies and applying them to create advanced solutions for patients in need. Their products aim to restore and regenerate damaged tissues, improving the quality of life for individuals suffering from chronic wounds and other tissue-related disorders.


   Company Address: 10 High Court Little Falls 7424 NJ
   Company Phone Number: 557-8914   Stock Exchange / Ticker: RGIN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Regenicin Inc

Regenicin Inc Releases Q2 2023 Financial Results with Significant Operating Shortfall of $-0.327836 Million

Regenicin Inc: A Closer Look at Its Q2 2023 Financial Results
The Medical Equipment & Supplies sector has been a major player in the healthcare industry, with bellwether companies leading the way in terms of financial performance. However, as the sector grows, smaller companies are also emerging and attempting to make a name for themselves.
Regenicin Inc is one such company that has caught the attention of investors. Recently, the company released its Q2 2023 financial results, indicating a significant operating shortfall of $-0.327836 million. Although the designated revenue has not been revealed, it can be compared to the company's Q2 2022 performance, which reported a similar operating shortfall of $-0.155513 million.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com